Protein phosphatases 2A as well as reactive oxygen species involved in tributyltin-induced apoptosis in mouse livers

Yali Zhang1, Yonggang Chen, Lijun Sun

  • 1Department of Biochemistry and Genetics, School of medicine, Zhejiang University, 866th Yu Hang Tang Road, 310058, Hangzhou, China.

Environmental Toxicology
|January 7, 2012
PubMed

Insights

Tributyltin (TBT) exposure in mice induces liver apoptosis by inhibiting protein phosphatase 2A (PP2A) and increasing reactive oxygen species (ROS). This triggers MAPK activation, leading to caspase-3 mediated cell death.

Area of Science:

  • Environmental Toxicology
  • Cellular Biology
  • Molecular Mechanisms

Background:

  • Tributyltin (TBT) is a toxic environmental pollutant with known in vitro effects.
  • Previous studies indicated TBT induces apoptosis via PP2A inhibition and JNK activation in human cells.

Purpose of the Study:

  • To validate in vitro findings on TBT-induced apoptosis in an in vivo mouse model.
  • To elucidate the molecular signaling pathway of TBT toxicity in mouse livers.

Main Methods:

  • Mice were orally administered varying doses of TBT (0-60 mg/kg).
  • Liver tissues were analyzed for PP2A activity, ROS, MAPK (ERK, JNK, p38) activation, Bax/Bcl-2 ratio, and caspase-3 levels.
  • Apoptosis was assessed using the TUNEL assay.

Main Results:

  • TBT exposure inhibited PP2A activity and increased ROS levels in mouse livers.
  • MAPK activation (ERK, JNK, p38) and an elevated Bax/Bcl-2 ratio were observed.
  • Caspase-3 activation and significant apoptosis were detected in TBT-treated livers.

Conclusions:

  • TBT-induced liver apoptosis involves PP2A inhibition and ROS elevation, activating MAPKs.
  • MAPK activation leads to altered Bax/Bcl-2 expression and caspase-3 activation, culminating in apoptosis.
  • This study details a novel in vivo mechanism for TBT-induced hepatotoxicity.

Related Concept Videos

Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...